A Case of Fascioliasis Treated Successfully Without Sequelae in a Japanese Expatriate Living in Jakarta

Masataro Norizuki, Tepepi Sasahara, Harumi Gomi, Yuji Morisawa, Noriko Takamura, Tsuneaki Kenzaka, Tetsuro Kobayashi, Yoshihiro Fujiya, Yasuyuki Kato, and Hiroyuki Matsuoka

1Center for Clinical Infectious Diseases, Jichi Medical University Hospital, Tochigi, Japan. 2Department of Infection and Immunity, School of Medicine, Jichi Medical University, Tochigi, Japan. 3Center for Global Health, Mito Kyodo General Hospital, University of Tsukuba, Ibaraki, Japan. 4Division of General Internal Medicine, Jichi Medical University Hospital, Tochigi, Japan. 5Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. 6Division of Medical Zoology, School of Medicine, Jichi Medical University, Tochigi, Japan.

ABSTRACT: A 46-year-old Japanese female expatriate living in Jakarta presented with intermittent fever lasting for a month. Although she was considered at low risk of Fasciola spp. infection because she lived in an upper-class residential area of the city, the patient presented with eosinophilia after consuming organic raw vegetables; in addition, contrast-enhanced computed tomography detected microabscesses in a tractlike pattern in the liver. These findings led to an early diagnosis of fascioliasis, which was successfully treated without sequelae. In any patient with a history of consuming raw vegetables, fascioliasis should be suspected regardless of where the patient has lived.

KEYWORDS: fascioliasis, Fasciola hepatica, Fasciola gigantica, triclabendazole, computed tomography

Introduction

Fascioliasis is a worldwide zoonosis caused by Fasciola spp. and is often neglected despite its common occurrence in endemic areas.1,2 If detected at an early stage, fascioliasis can be treated successfully; however, the disease in the advanced stages can cause liver fibrosis, hepatic cirrhosis, and sometimes death.3,4 Therefore, early detection and treatment are important. However, owing to its nonspecific symptoms and observational findings, human fascioliasis is difficult to diagnose.5-7 Some clinicians have limited experience with human fascioliasis in nonendemic countries. And this situation leads to misdiagnosis or delayed treatment. We herein report a case of fascioliasis in a traveler from Jakarta, Indonesia, who was diagnosed at an early stage based on a detailed history of the patient, eosinophilia, and the characteristic findings on computed tomography (CT), resulting in successful treatment without any sequelae. Informed consent was obtained from the patient.

Case Report

A 46-year-old Japanese woman without a medical history expatriated to Jakarta, Indonesia, for 5 years. She lived in an upper-class residential area, in a clean environment. Around the time she returned to Japan, 1.5 months prior to her visit to our clinic, the patient started experiencing a dry cough, which subsided after several days. One month prior to her visit, she developed a fever of 40 °C that persisted for several days accompanied by malaise, followed by fever and malaise every week. Two days prior to her visit, the patient experienced fever and epigastric pain. The patient had no history of consumption of raw seafood; however, the patient had been eating organic raw vegetables on a daily basis, including watercress.

At admission, her body temperature was 35 °C, vital signs were stable, and the liver was enlarged and tender. She had eosinophilia (eosinophil count, 3,465 cells/μL) and mild hepatic dysfunction (aspartate transaminase, 37 U/L; alanine transaminase, 60 U/L; γ-glutamyl transpeptidase, 70 U/L; and alkaline phosphatase, 398 U/L). Hyperbilirubinemia was absent. Three of the stool specimens were negative, the latter for ova, cysts, and parasites, examined under a microscope. Enhanced CT showed multiple microabscesses arranged in a tractlike pattern with ring enhancement in the right lobe of the liver (Fig. 1). Endoscopic retrograde cholangiopancreatography did not show worms in the bile duct, and no ova were detected in the bile examined under a microscope. The diagnosis of fascioliasis was confirmed by demonstration of specific antibodies to Fasciola sp. using the Ouchterlony double-diffusion test (Fig. 2).

CITATION: Norizuki et al. A Case of Fascioliasis Treated Successfully Without Sequelae in a Japanese Expatriate Living in Jakarta. Clinical Medicine Insights: Case Reports 2015:8 61–63 doi: 10.4137/CCRep.526578.

RECEIVED: March 24, 2015. RESUBMITTED: June 08, 2015. ACCEPTED FOR PUBLICATION: June 11, 2015.

ACADEMIC EDITOR: Athavale Nandkishor, Associate Editor

TYPE: Case Report

FUNDING: Triclabendazole was provided by the Research Group on Chemotherapy of Tropical Diseases funded by research grant from the Ministry of Health, Labour and Welfare, Japan (H25-iryogijutsu-shitei-012). The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.

COMPETING INTERESTS: HG reports lecture honoraria from Astellas, Taisho Toyama Inc, Meiji, Daiichi-Sankyo, Pfizer, Kyorin and Dainippon Sumitomo Pharma, and moderator honorarium from Radio Meter, Japan, outside the work presented here. Other authors disclose no potential conflicts of interest.

CORRESPONDENCE: protozoa@jichi.ac.jp

COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

Paper subject to independent expert blind peer review by minimum of two reviewers. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Published by Libertas Academica. Learn more about this journal.
For treatment, 500 mg (10 mg/kg) triclabendazole (Egaten™, Novartis Pharma AG, Switzerland) was orally administered two times at 12-h intervals. After the initiation of triclabendazole administration, the fever and malaise resolved immediately. Her eosinophil count decreased to 1,966/µL in 1 month, 624/µL in 2 months, and 273/µL in 3 months, reaching the normal range. Contrast-enhanced CT performed a year later showed almost complete disappearance of the multiple nodular lesions (Fig. 3).

**Discussion**

Fascioliasis is a common trematodiasis distributed worldwide mainly in human-endemic areas and animal-endemic areas.\(^9\) However, in several nonendemic countries such as Japan, most clinicians lack experience and knowledge about human fascioliasis. Therefore, the disease can sometimes be excluded from differential diagnosis and overlooked.\(^6,7\)

Adult *Fasciola* spp., the causative agent for fascioliasis, inhabit the bile duct of ruminants such as cattle and sheep, which then pass their ova in stool. The eggs become embryo-nated in fresh water. The eggs release miracidium. The miracidium develops and invades a suitable snail (*Galba/Fosaria* group, genus *Radix* and *Pseudosuccinea*) as an intermediate host. In the snail, the miracidium develop to the sporocysts, rediae, then cercaria. The cercaria are released from the snails and encyst as metacercaria on aquatic plants such as watercress.\(^3,5\) Humans can accidentally become infected as the final host by eating raw aquatic plants or drinking water contaminated with metacercaria.\(^1\) Therefore, the incidence of fascioliasis is considered scarce in urban areas but concentrated in rural areas, where these conditions are likely to be met.\(^4\)

The present patient had lived in a clean environment in an urban area of Jakarta. Thus, the risk of becoming infected with *Fasciola* spp. would have been considered low. However, she had routinely consumed organic raw vegetables grown at an organic farm that also raised cattle. Therefore, contaminated organic raw vegetables were considered the source of infection.

When ingested by humans, immature larvae invade the abdominal cavity via the small-intestinal wall 2 hours after ingestion, grow into juveniles, reach the liver within 6 days after excystment, and migrate into the liver through the hepatic capsule, causing the formation of linear cystic lesions.\(^1\) In the liver, juveniles migrate for 5–6 weeks. This is considered the invasive or acute phase\(^1,10\) and is distinctive on CT,\(^11\) as in the present case (Fig. 1). During this phase, the patient...
might experience right hypochondrial pain, fever, nausea, vomiting, and cough, and eosinophilia is common. Because the patient in the present case exhibited all these characteristics, she was considered to be in the invasive or acute phase. The biliary phase follows next, when juveniles migrate into the bile duct where they become sexually mature and deposit eggs at least 6 months from the beginning of the invasive or acute phase. It is possible to detect the eggs in both stool and bile. Chronic-stage fascioliasis may be asymptomatic but can develop into irreversible liver fibrosis or liver cirrhosis as a result of recurrent cholangitis caused by worm-induced biliary obstruction. Adult worms can also cause irreversible lesions by invading various organs other than the liver, such as the gastrointestinal tract, abdominal wall, lung, heart, brain, and eye (ectopic fascioliasis).

Because of the effects in the more advanced biliary phase, it is important to detect and treat fascioliasis early. While the presence of worms or ova provides a direct diagnosis of fascioliasis, a patient in the invasive or acute phase does not have worms in the bile duct or ova in the bile. Therefore, even if worm or ova is negative, this result could not rule out the possibility of fascioliasis. If the clinician does not have knowledge of the lifecycle of fascioliasis, diagnosis is difficult during the invasive or acute phase, which can consequently lead to a misdiagnosis or delayed diagnosis. Although fascioliasis during the invasive or acute phase can only be definitively diagnosed via serological testing, contrast-enhanced CT can sometimes significantly help, as in the present case. However, clinicians or radiologists who have limited experience with human fascioliasis often misdiagnose lesions observed on contrast-enhanced CT as a malignant tumor, causing the patient to undergo liver biopsy or hepatectomy. Therefore, it is very important that clinicians and radiologists outside endemic regions be aware of the typical contrast-enhanced CT findings of fascioliasis.

Triclabendazole is the first-line treatment for fascioliasis, with a cure rate of 78%–100% at doses of 10 mg/kg. Unlike other helminth infections, treatment with praziquantel is not effective. Triclabendazole resistance concerned livestock in animal-endemic areas. Fortunately, the symptoms of our patient disappeared rapidly and eosinophilia and CT findings were improved, and there was no triclabendazole in our case.

The present case with fascioliasis was diagnosed and treated at an early stage of infection based on a detailed patient history, eosinophilia, and typical CT findings. Fascioliasis is no longer a disease limited to human-endemic areas or animal-endemic areas. It might be diagnosed in any areas across the world. Therefore, all clinicians should acquire knowledge about fascioliasis. Fascioliasis should be considered in the differential diagnosis of any patient who consumes raw vegetables and presents with gastrointestinal symptoms and eosinophilia, regardless of the patient’s residence and living situation. The characteristic contrast-enhanced CT findings may provide a clue to the potential presence of fascioliasis, and treatment should be initiated immediately after a serological diagnosis.

**Author Contributions**

Conceived and designed the experiments: MN, TS. Contributed to the acquisition of the clinical data: MN, NT, TK, YF, YK, HM. Analyzed the data: NT, TK, YF, YK, HM. Wrote the first draft of the manuscript: MN. Contributed to the writing of the manuscript: TS, YM. Agreed with manuscript results and conclusions: MN, TS, HG, YM, NT, TK, YF, YK, HM. Jointly developed the structure and arguments for the paper: MN, TS. Made critical revisions and approved final version: MN, TS, HG, YM, NT, TK, YF, YK, HM. All authors reviewed and approved of the final manuscript.

**REFERENCES**

1. Mas-Coma S, Valero MA, Bargues MD. Chapter 4: fascioliasis. In: Toledo R, Fried B, eds. *Digenetic Trematodes*. Vol 766. New York: Advances in Experimental Medicine and Biology Series, Springer Media + Business Media; 2014:77–114.

2. World Health Organization. Fascioliasis: Infection with the “Neglected” Nematode *Fasciola*. 2009. Available at: http://www.who.int/neglected_diseases/integrated_media/integrated_media_fascioliasis/en/. Accessed March 20, 2015.

3. Mas-Coma S, Abravanel VH, Valero MA. Neurological and ocular fascioliasis in humans. Adv Parasitol. 2014;84:27–149.

4. Ashraf K, Bargues MD, ONeill S, Mas-Coma S. Fascioliasis a worldwide parasitic disease of importance in travel medicine. Travel Med Infect Dis. 2014;12:636–49.

5. Mas-Coma S, Bargues MD, Valero MA. Diagnosis of human fascioliasis by stool and blood techniques: update for the present global scenario. Parasitology. 2014;141(Special Issue):1918–46.

6. Behar JM, Winston JS, Borgstein R. Hepatic fascioliasis at a London hospital - the importance of recognising typical radiological features to avoid a delay in diagnosis. Br J Radiol. 2009;82:e189–93.

7. Kung ML, Teo CH, Wangsaichong GK, Giron DM, Wilder-Smith A. Fasciola hepatica in a New Zealander traveler. J Travel Med. 2008;15:136–9.

8. Matsuoka H, Tongu Y, Aji T, et al. Seven cases of human fascioliasis in and around Okayama prefecture. Okayama Igakkai zasshi. 1987;99:1419–502.

9. Mas-Coma S, Valero MA, Bargues MD. *Fasciola*, lymphoid and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv Parasitol. 2009;69:41–146.

10. Price TA, Tuazon CU, Simon GL. Fascioliasis: case reports and review. Clin Infect Dis. 1995;17:426–30.

11. Han JK, Choi BI, Cho JM, et al. Radiological findings of human fascioliasis. Abdom Imaging. 1993;18:261–4.

12. Keiser J, Blok D, Büscher G, Utringer J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs. 2005;14:1513–26.